CD86 and neoplasm: To characterize potential immune responses in mice treated with PanNV plus αMSLN, we further performed flow cytometry to evaluate the proportion of matured DCs (CD11c+, CD80+ and CD86+) in lymph nodes (LNs), effector memory CD8+ T cells (CD44+ and CD62L−) in spleen and the infiltration and activation of T cells in tumor tissue obtained on the day 18, respectively.